Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SALIM VIRANI and SANKAR NAVANEETHAN.
SALIM VIRANI
Connection Strength
4.787
SANKAR NAVANEETHAN
  1. Omega-3 Fatty Acids (Fish Oil) Supplementation and Albuminuria: Not a Slam Dunk. J Am Heart Assoc. 2017 07 14; 6(7).
    View in: PubMed
    Score: 0.601
  2. Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD. J Am Soc Nephrol. 2024 Aug 26.
    View in: PubMed
    Score: 0.246
  3. Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study. Cardiorenal Med. 2024; 14(1):34-44.
    View in: PubMed
    Score: 0.235
  4. Racial and Ethnic Disparities and Facility-Level Variation in GLP-1 RA Prescription among US Veterans with CKD. Clin J Am Soc Nephrol. 2023 11 01; 18(11):1479-1482.
    View in: PubMed
    Score: 0.228
  5. Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Am J Nephrol. 2023; 54(3-4):126-135.
    View in: PubMed
    Score: 0.225
  6. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.225
  7. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. Am J Kidney Dis. 2023 07; 82(1):53-62.e1.
    View in: PubMed
    Score: 0.220
  8. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
    View in: PubMed
    Score: 0.208
  9. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
    View in: PubMed
    Score: 0.208
  10. Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. Am Heart J. 2022 06; 248:160-162.
    View in: PubMed
    Score: 0.204
  11. Effects of the 2021 CKD-EPI Creatinine eGFR Equation among a National US Veteran Cohort. Clin J Am Soc Nephrol. 2022 02; 17(2):283-285.
    View in: PubMed
    Score: 0.203
  12. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2021 09 27; 36(10):1893-1899.
    View in: PubMed
    Score: 0.201
  13. Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Res Care. 2021 07; 9(1).
    View in: PubMed
    Score: 0.198
  14. Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
    View in: PubMed
    Score: 0.197
  15. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 02 23; 143(8):e254-e743.
    View in: PubMed
    Score: 0.192
  16. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020 02 01; 35(2):312-319.
    View in: PubMed
    Score: 0.179
  17. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Curr Atheroscler Rep. 2019 06 22; 21(9):32.
    View in: PubMed
    Score: 0.172
  18. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
    View in: PubMed
    Score: 0.165
  19. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol. 2018 Jul - Aug; 12(4):1061-1071.e7.
    View in: PubMed
    Score: 0.158
  20. Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database. Clin Cardiol. 2017 Nov; 40(11):1055-1060.
    View in: PubMed
    Score: 0.151
  21. Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States. J Am Coll Cardiol. 2024 May 07; 83(18):1824-1826.
    View in: PubMed
    Score: 0.060
  22. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023 02 21; 147(8):e93-e621.
    View in: PubMed
    Score: 0.055
  23. Natriuretic peptides, extracellular volume, and subclinical cardiovascular changes in chronic kidney disease stages 1-3: a pilot study. J Investig Med. 2022 Jul 19.
    View in: PubMed
    Score: 0.053
  24. Revisiting diuretic choice in chronic kidney disease. Curr Opin Nephrol Hypertens. 2022 09 01; 31(5):406-413.
    View in: PubMed
    Score: 0.053
  25. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.051
  26. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 02 22; 145(8):e153-e639.
    View in: PubMed
    Score: 0.051
  27. Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5. Hypertension. 2021 03 03; 77(3):948-959.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.